Antitumor Effects of Human Monoclonal Antibodies on Human Malignant Glioma Xenografts and Their Clinical Application
Human anaplastic gliomas still have a poor prognosis despite current aggressive therapies such as microsurgery, advanced radiation therapy, combined chemotherapy and/or immuno-therapy. It has been widely reported that a major limitation of these treatments is the lack of tumor specificity. Hybridoma technology has made it possible to generate large quantities of monoclonal antibodies (MAB) which are highly specific to human malignant tumors. Such tumor-associated MABs are potentially powerful tools in the diagnosis and treatment of human malignant tumors. A large number of monoclonal antibodies has been produced by hybridomas from mouse × mouse or mouse × human cells, and those antibodies were used in the diagnosis and the treatment of human cancers [1–3].
KeywordsAntitumor Effect Malignant Glioma Human Glioma Human Monoclonal Antibody Athymic Nude Mouse
Unable to display preview. Download preview PDF.
- 6.Hagiwara H, Ohtake H, Yuasa H (1985) Proliferation and antibody production of human × human hybridoma in serum-free media. In: Murakami H, Yamane I, Barnes DW, et al. (eds) Growth and differentiation of cells in defined environment. Springer Heidelberg, pp 1–6Google Scholar